UA95945C2 - Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12 - Google Patents

Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12

Info

Publication number
UA95945C2
UA95945C2 UAA200810850A UAA200810850A UA95945C2 UA 95945 C2 UA95945 C2 UA 95945C2 UA A200810850 A UAA200810850 A UA A200810850A UA A200810850 A UAA200810850 A UA A200810850A UA 95945 C2 UA95945 C2 UA 95945C2
Authority
UA
Ukraine
Prior art keywords
prostate cancer
androgen
deprivation therapy
cancer
androgen deprivation
Prior art date
Application number
UAA200810850A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дейл Людвиг
Стефен Р. Плаймейт
Original Assignee
Имклоун Ллк
Юниверсити Оф Вашингтон
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклоун Ллк, Юниверсити Оф Вашингтон filed Critical Имклоун Ллк
Publication of UA95945C2 publication Critical patent/UA95945C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Данное изобретение касается способа лечения рака предстательной железы, который включает – отдельно, одновременно или последовательно – проведение терапии депривацией андрогенов в комбинации с введением IMC-А12.
UAA200810850A 2006-02-03 2007-02-03 Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12 UA95945C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76507206P 2006-02-03 2006-02-03

Publications (1)

Publication Number Publication Date
UA95945C2 true UA95945C2 (ru) 2011-09-26

Family

ID=38345750

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200810850A UA95945C2 (ru) 2006-02-03 2007-02-03 Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12

Country Status (17)

Country Link
US (1) US7972600B2 (ru)
EP (1) EP1984011A4 (ru)
JP (1) JP5198289B2 (ru)
KR (1) KR101353706B1 (ru)
CN (1) CN101484587B (ru)
AP (1) AP2008004569A0 (ru)
AU (1) AU2007212447B2 (ru)
CA (1) CA2641310C (ru)
CR (1) CR10188A (ru)
EA (1) EA017265B1 (ru)
EC (1) ECSP088706A (ru)
IL (1) IL193203A0 (ru)
MX (1) MX2008009977A (ru)
NO (1) NO20083444L (ru)
UA (1) UA95945C2 (ru)
WO (1) WO2007092453A2 (ru)
ZA (1) ZA200807012B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092276A1 (en) 2007-02-01 2008-08-07 Dolby Laboratories Licensing Corporation Calibration of displays having spatially-variable backlight
RU2010119922A (ru) * 2007-10-19 2011-11-27 Фарма Мар, С.А. (Es) Усовершенствованное противоопухолевое лечение
US9084770B2 (en) * 2008-10-14 2015-07-21 Antisense Therapeutics, Ltd. Modulation of insulin like growth factor I receptor expression in cancer
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
US20100214282A1 (en) 2009-02-24 2010-08-26 Dolby Laboratories Licensing Corporation Apparatus for providing light source modulation in dual modulator displays
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
KR101426134B1 (ko) * 2011-09-26 2014-08-06 한화케미칼 주식회사 항 ｉｇｆ-1ｒ 단일클론 항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
WO2013119864A1 (en) * 2012-02-07 2013-08-15 University Of Central Florida Research Foundation, Inc. Increasing taxane sensitivity in cancer cells
WO2014137946A1 (en) * 2013-03-04 2014-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods of inhibiting igf-1r activation or downtream signalling thereof to reduce radiation-induced cellular senescence
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CA2921156A1 (en) * 2013-09-19 2015-03-26 Glaxosmithkline Llc Combination drug therapy
WO2021113794A1 (en) * 2019-12-06 2021-06-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Clinical decision support for personalized adaptive prostate cancer therapy
CN113512116B (zh) 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585344A (en) * 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
US4774321A (en) * 1986-12-01 1988-09-27 Massachusetts Institute Of Technology DP100 EGF and insulin-binding protein from Drosophila cells
US5200509A (en) * 1987-04-06 1993-04-06 Celtrix Pharmaceuticals, Inc. Human somatomedin carrier protein subunits and process for producing them; recombinant DNA molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
JP2648951B2 (ja) 1987-04-06 1997-09-03 セルトリックス ファーマシュウティカルズ，インク 人体のソマトメジン担体蛋白質サブユニットとこれらの製法
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5705157A (en) * 1989-07-27 1998-01-06 The Trustees Of The University Of Pennsylvania Methods of treating cancerous cells with anti-receptor antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
WO1992003152A1 (en) * 1990-08-28 1992-03-05 Chiron Corporation New insulin-like growth factor binding protein (igfbp-4)
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5262308A (en) * 1992-01-28 1993-11-16 Thomas Jefferson University Cell lines which constitutively express IGF-1 and IGF-1 R
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
US5869337A (en) * 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
WO1994023034A2 (en) * 1993-04-06 1994-10-13 Cedars-Sinai Medical Center Variant insulin-like growth factor i receptor subunits and methods for use thereof
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US5597700A (en) * 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
DE69518919T2 (de) * 1994-06-24 2001-03-29 Vladimir P Torchilin Autoantikörper enthaltende zusammensetzung für tumorbehandlung und -vorbeugung
US5939269A (en) * 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
EP0817775B1 (en) 1995-03-30 2001-09-12 Pfizer Inc. Quinazoline derivatives
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US6084085A (en) * 1995-11-14 2000-07-04 Thomas Jefferson University Inducing resistance to tumor growth with soluble IGF-1 receptor
AUPN999096A0 (en) 1996-05-22 1996-06-13 Northstar Biologicals Pty Ltd Peptides, antibodies, vaccines & uses thereof
US5798266A (en) * 1996-08-27 1998-08-25 K-Quay Enterprises, Llc Methods and kits for obtaining and assaying mammary fluid samples for breast diseases, including cancer
US6071891A (en) * 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
TR200000415T2 (tr) * 1997-08-15 2000-08-21 Cephalon Inc. Prostat kanserinin tedavi edilmesi için birleşimler.
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
US6875741B2 (en) * 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
TR200100936T2 (tr) * 1998-10-05 2001-08-21 Pharmexa A/S Terapötik aşılama
EP1006184A1 (en) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6316462B1 (en) * 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US20020103345A1 (en) 2000-05-24 2002-08-01 Zhenping Zhu Bispecific immunoglobulin-like antigen binding proteins and method of production
US7329745B2 (en) * 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
US20030165502A1 (en) * 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
WO2001098493A1 (fr) * 2000-06-15 2001-12-27 Kyowa Hakko Kogyo Co., Ltd Proteine de liaison de facteur de croissance insulinoide
US8153121B2 (en) * 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
WO2002053596A2 (en) * 2001-01-05 2002-07-11 Pfizer Inc. Antibodies to insulin-like growth factor i receptor
US7071300B2 (en) * 2001-03-14 2006-07-04 Genentech, Inc. IGF antagonist peptides
WO2002087618A1 (fr) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Methode de prevention et de traitement du cancer
US7666414B2 (en) * 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US7553485B2 (en) * 2002-01-18 2009-06-30 Pierre Fabre Medicament Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof
US7241444B2 (en) * 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
JP4606739B2 (ja) 2002-01-18 2011-01-05 ピエール、ファーブル、メディカマン 新規抗ｉｇｆ−ｉｒ抗体およびその使用
JP4563171B2 (ja) 2002-05-24 2010-10-13 シェーリング コーポレイション 中和ヒト抗ｉｇｆｒ抗体
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
EP2366718A3 (en) * 2002-06-28 2012-05-02 Domantis Limited Ligand
CA2494310A1 (en) * 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP2006517581A (ja) 2003-02-13 2006-07-27 ファイザー・プロダクツ・インク 抗インスリン様増殖因子ｉ受容体抗体の使用
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
WO2005016970A2 (en) * 2003-05-01 2005-02-24 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
WO2005014618A2 (en) * 2003-08-08 2005-02-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
UA85058C2 (ru) * 2003-08-13 2008-12-25 Пфайзер Продактс Инк. Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir)
CA2540133A1 (en) * 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. Drugs for treating cancer
TW200526684A (en) * 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
EP1737493B1 (en) 2004-02-25 2011-06-29 Dana-Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor -1 for inhibiting tumor cell growth
CA2560305C (en) * 2004-03-19 2016-07-05 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
EP2322215A3 (en) 2004-07-16 2011-09-28 Pfizer Products Inc. Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
US20070010537A1 (en) * 2004-08-20 2007-01-11 Kazumasa Hamamura Fused pyramidine derivative and use thereof
CA2589885A1 (en) 2004-12-03 2006-06-08 Schering Corporation Biomarkers for pre-selection of patients for anti-igf1r therapy
WO2006068829A1 (en) * 2004-12-21 2006-06-29 Alcon, Inc. Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EA200702239A1 (ru) * 2005-04-15 2008-10-30 Иммьюноджен, Инк. Уничтожение гетерогенной или смешанной клеточной популяции в опухолях
BRPI0611984A2 (pt) * 2005-06-17 2009-07-07 Imclone Systems Inc uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
US20070009970A1 (en) * 2005-07-08 2007-01-11 Predicant Biosciences, Inc. Biological patterns for diagnosis and treatment of cancer
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
CA2619298C (en) 2005-08-26 2017-07-04 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
RS52357B (en) * 2005-12-13 2012-12-31 Medimmune Limited BINDING PROTEINS SPECIFIC TO INSULIN SIMILAR GROWTH FACTORS AND THEIR USE

Also Published As

Publication number Publication date
JP2009525348A (ja) 2009-07-09
EP1984011A4 (en) 2010-08-18
WO2007092453A3 (en) 2008-12-24
US7972600B2 (en) 2011-07-05
ECSP088706A (es) 2008-10-31
IL193203A0 (en) 2009-08-03
EP1984011A2 (en) 2008-10-29
ZA200807012B (en) 2009-12-30
JP5198289B2 (ja) 2013-05-15
AU2007212447A1 (en) 2007-08-16
CN101484587B (zh) 2014-02-12
EA017265B1 (ru) 2012-11-30
EA200870231A1 (ru) 2009-12-30
WO2007092453A2 (en) 2007-08-16
NO20083444L (no) 2008-10-31
AP2008004569A0 (en) 2008-08-31
CR10188A (es) 2008-11-18
KR101353706B1 (ko) 2014-02-18
US20090175868A1 (en) 2009-07-09
MX2008009977A (es) 2009-02-27
CN101484587A (zh) 2009-07-15
CA2641310A1 (en) 2007-08-16
AU2007212447B2 (en) 2013-02-21
KR20080090566A (ko) 2008-10-08
CA2641310C (en) 2013-08-20

Similar Documents

Publication Publication Date Title
UA95945C2 (ru) Способ лечения рака предстательной железы, который включает проведение терапии депривацией андрогенов в комбинации с введением imc-а12
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
Zhu et al. Targeted therapy in her2-positive metastatic breast cancer: a review of the literature
MX2009006779A (es) Antagonistas especificos para terapia con adyuvantes y neo-adyuvantes y el tratamiento de tumores en etapa temprana.
TW200621240A (en) Cancer treatments
Tunn The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight
WO2009137543A3 (en) Methods for breast cancer screening and treatment
WO2007011372A3 (en) Therapeutic and prognostic factor yy1 in human cancer
MX346924B (es) Compuestos de diarilhidantoina.
IN2012DN01964A (ru)
WO2005016234A3 (en) Compositions, methods, apparatuses, and systems for singlet oxygen delivery
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
WO2005000212A8 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
WO2008060899A3 (en) Breast cancer screening and treatment methods
WO2022031642A3 (en) Uses of glucocorticoid receptor (gr) antagonist and androgen receptor (ar) degrader combinations
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
WO2006060819A3 (en) Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells
WO2009114658A3 (en) Androgen receptor inactivation contributes to antitumor efficacy of cyp17 inhibitors in prostate cancer
Polkinghorn et al. Improving outcomes in high-risk prostate cancer with radiotherapy
Díez et al. Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate-and high-risk prostate cancer
WO2009073139A3 (en) Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
AU4338501A (en) Combination chemotherapy
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
MX2022014004A (es) Tratamientos del cancer de prostata con combinaciones de acetato de abiraterona y niraparib.
Milecki et al. Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?